GENEVA—Evidence presented at the 2015 European Lung Cancer conference from the large SQUIRE multicenter open label study points to the fact that older patients with squamous non small cell lung cancer
GENEVA—Evidence presented at the 2015 European Lung Cancer conference from the large SQUIRE multicenter open label study points to the fact that older patients with squamous non small cell lung cancer can benefit from a three drug regimen including the EGFR-targeted agent necitumumab. Nicholas Thatcher, MD PhD—who is Professor of Oncology at the University of Manchester—explained to Oncology Times reporter Peter Goodwin how the outcome data from SQUIRE give reassurance that older patients can benefit from such new combinations—without the need to resort to more gentle regimens—provided attention is paid to the influence of co-morbidities.